IN2014DN10084A - - Google Patents
Info
- Publication number
- IN2014DN10084A IN2014DN10084A IN10084DEN2014A IN2014DN10084A IN 2014DN10084 A IN2014DN10084 A IN 2014DN10084A IN 10084DEN2014 A IN10084DEN2014 A IN 10084DEN2014A IN 2014DN10084 A IN2014DN10084 A IN 2014DN10084A
- Authority
- IN
- India
- Prior art keywords
- androgen receptor
- receptor modulator
- trifluoromethylpyridin
- diazaspiro
- methylbenzamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Described herein are amorphous and crystalline forms of the androgen receptor modulator 4 -[7- (6- cyano- 5- trifluoromethylpyridin 3- yl)- 8 oxo -6- thioxo- 5, 7 diazaspiro[3.4]oct- 5- yl]- 2- fluoro- N- methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656888P | 2012-06-07 | 2012-06-07 | |
| PCT/US2013/044116 WO2013184681A1 (en) | 2012-06-07 | 2013-06-04 | Crystalline forms of an androgen receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10084A true IN2014DN10084A (en) | 2015-08-21 |
Family
ID=49712550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10084DEN2014 IN2014DN10084A (en) | 2012-06-07 | 2013-06-04 |
Country Status (45)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| BR112014014767A2 (en) | 2011-12-16 | 2017-06-13 | Olema Pharmaceuticals Inc | new benzopyran compounds, compositions and uses thereof |
| UA123142C2 (en) | 2012-06-07 | 2021-02-24 | Арагон Фармасьютікалз, Інк. | CRYSTAL FORMS OF THE ANDROGEN RECEPTOR MODULATOR |
| TWI673051B (en) | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | Formulations of enzalutamide |
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (en) * | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| WO2016029776A1 (en) * | 2014-08-26 | 2016-03-03 | Astar Biotech Llc | Protein kinase inhibitors |
| RS62421B1 (en) | 2014-12-05 | 2021-10-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| CN114886852A (en) * | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | Anticancer composition |
| WO2016090101A1 (en) | 2014-12-05 | 2016-06-09 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| US9888543B2 (en) | 2014-12-19 | 2018-02-06 | Lutron Electronics Co, Inc. | Multi-channel lighting fixture having multiple light-emitting diode drivers |
| EA201892828A1 (en) | 2016-06-03 | 2019-05-31 | Арагон Фармасьютикалз, Инк. | CONTRA-TRAY COMPOSITIONS |
| RU2019121700A (en) | 2016-12-13 | 2021-01-15 | Ватсон Лэборетериз Инк. | SOLID FORMS OF APALUTAMIDE |
| KR20240096623A (en) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | Anti-androgens for the treatment of non-metastatic castration-resistant |
| WO2019135254A1 (en) | 2018-01-02 | 2019-07-11 | Mylan Laboratories Limited | Apalutamide polymorphs and their preparation thereof |
| KR20210023987A (en) | 2018-06-20 | 2021-03-04 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | Crystal form of ARN-509, its manufacturing method and its use |
| WO2020049598A2 (en) | 2018-09-08 | 2020-03-12 | Cipla Limited | Apalutamide polymorphs |
| IT201900003839A1 (en) | 2019-03-15 | 2020-09-15 | Olon Spa | STABLE AMORPHOUS APALUTAMIDE SYNTHESIS |
| WO2020234817A1 (en) * | 2019-05-21 | 2020-11-26 | Laurus Labs Limited | Polymorphic forms of apalutamide and its preparation thereof |
| IT201900010593A1 (en) | 2019-07-01 | 2021-01-01 | Dipharma Francis Srl | CRYSTALLINE FORM OF AN ANDROGEN RECEPTOR INHIBITOR |
| EP4017848A1 (en) * | 2019-08-22 | 2022-06-29 | Dr. Reddy's Laboratories Ltd. | Process for the preparation of apalutamide |
| IT201900015974A1 (en) | 2019-09-10 | 2021-03-10 | Olon Spa | STABLE CRYSTALLINE APALUTAMIDE IN PURE FORM AND PROCESS FOR ITS PREPARATION |
| CN110590740A (en) * | 2019-09-20 | 2019-12-20 | 武汉大学 | Apaglus amine compound and pharmaceutical preparation thereof |
| US12606539B2 (en) | 2020-09-04 | 2026-04-21 | Synthon B.V. | Process for preparation of apalutamide |
| CN112679468A (en) * | 2021-01-05 | 2021-04-20 | 四川科伦药物研究院有限公司 | Crystal form of apatamide, preparation method and application |
| WO2023143090A1 (en) * | 2022-01-25 | 2023-08-03 | 成都苑东生物制药股份有限公司 | Novel crystalline form of apalutamide solvate and preparation method therefor |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems, and methods for modulating a target gene |
| CN115536634B (en) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | A kind of synthetic method of apalutamide |
| CN116332907A (en) * | 2023-03-16 | 2023-06-27 | 奥锐特药业股份有限公司 | A kind of preparation method of amorphous apalutamide |
| AU2025209171A1 (en) * | 2024-01-18 | 2026-05-28 | Nanoform Finland Oyj | Composition comprising crystalline nanosized apalutamide |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| CN101032483B (en) * | 2006-03-09 | 2011-05-04 | 陈德桂 | Hydantoin derivative for adjusting estrogen receptor activity and application thereof |
| BRPI0709771B1 (en) | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Compound and pharmaceutical composition |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| EP3124481B1 (en) * | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| UA123142C2 (en) | 2012-06-07 | 2021-02-24 | Арагон Фармасьютікалз, Інк. | CRYSTAL FORMS OF THE ANDROGEN RECEPTOR MODULATOR |
| KR20210023987A (en) | 2018-06-20 | 2021-03-04 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | Crystal form of ARN-509, its manufacturing method and its use |
-
2013
- 2013-06-04 UA UAA201702779A patent/UA123142C2/en unknown
- 2013-06-04 SI SI201331894T patent/SI3533792T1/en unknown
- 2013-06-04 PE PE2020000234A patent/PE20200795A1/en unknown
- 2013-06-04 CA CA3114726A patent/CA3114726A1/en active Pending
- 2013-06-04 KR KR1020197033592A patent/KR102195916B1/en active Active
- 2013-06-04 PE PE2019002096A patent/PE20200725A1/en unknown
- 2013-06-04 RS RS20200913A patent/RS60617B1/en unknown
- 2013-06-04 PL PL13800681T patent/PL2858985T3/en unknown
- 2013-06-04 DK DK19169275.5T patent/DK3533792T3/en active
- 2013-06-04 MX MX2014015005A patent/MX356754B/en active IP Right Grant
- 2013-06-04 KR KR1020157000266A patent/KR102062024B1/en active Active
- 2013-06-04 BR BR112014030678A patent/BR112014030678A2/en not_active Application Discontinuation
- 2013-06-04 ES ES18157435T patent/ES2809738T3/en active Active
- 2013-06-04 ES ES19169275T patent/ES2875932T3/en active Active
- 2013-06-04 PT PT191692755T patent/PT3533792T/en unknown
- 2013-06-04 EP EP21171579.2A patent/EP3922629A1/en active Pending
- 2013-06-04 SM SM20180311T patent/SMT201800311T1/en unknown
- 2013-06-04 HU HUE19169275A patent/HUE054595T2/en unknown
- 2013-06-04 LT LTEP18157435.1T patent/LT3348553T/en unknown
- 2013-06-04 PT PT181574351T patent/PT3348553T/en unknown
- 2013-06-04 IL IL320522A patent/IL320522A/en unknown
- 2013-06-04 AU AU2013271751A patent/AU2013271751B2/en active Active
- 2013-06-04 CA CA2875767A patent/CA2875767C/en active Active
- 2013-06-04 JP JP2015516121A patent/JP6182209B2/en active Active
- 2013-06-04 NZ NZ702203A patent/NZ702203A/en unknown
- 2013-06-04 TW TW102119817A patent/TWI532732B/en active
- 2013-06-04 SM SM20200496T patent/SMT202000496T1/en unknown
- 2013-06-04 CA CA3055660A patent/CA3055660A1/en not_active Abandoned
- 2013-06-04 LT LTEP13800681.2T patent/LT2858985T/en unknown
- 2013-06-04 SI SI201331010T patent/SI2858985T1/en unknown
- 2013-06-04 SG SG11201408140QA patent/SG11201408140QA/en unknown
- 2013-06-04 HR HRP20180902TT patent/HRP20180902T1/en unknown
- 2013-06-04 CR CR20190331A patent/CR20190331A/en unknown
- 2013-06-04 PL PL18157435T patent/PL3348553T3/en unknown
- 2013-06-04 DK DK13800681.2T patent/DK2858985T3/en active
- 2013-06-04 UA UAA201500086A patent/UA115665C2/en unknown
- 2013-06-04 SM SM20210355T patent/SMT202100355T1/en unknown
- 2013-06-04 HU HUE18157435A patent/HUE050357T2/en unknown
- 2013-06-04 CN CN201380041652.3A patent/CN104619692A/en active Pending
- 2013-06-04 NZ NZ717683A patent/NZ717683A/en unknown
- 2013-06-04 EP EP13800681.2A patent/EP2858985B1/en active Active
- 2013-06-04 CA CA3008345A patent/CA3008345C/en active Active
- 2013-06-04 EP EP18157435.1A patent/EP3348553B1/en not_active Revoked
- 2013-06-04 CN CN201610202980.2A patent/CN105693692A/en active Pending
- 2013-06-04 EP EP19169275.5A patent/EP3533792B1/en active Active
- 2013-06-04 RS RS20180680A patent/RS57370B1/en unknown
- 2013-06-04 PT PT138006812T patent/PT2858985T/en unknown
- 2013-06-04 DK DK18157435.1T patent/DK3348553T3/en active
- 2013-06-04 ME MEP-2018-158A patent/ME03081B/en unknown
- 2013-06-04 IN IN10084DEN2014 patent/IN2014DN10084A/en unknown
- 2013-06-04 HU HUE13800681A patent/HUE038082T2/en unknown
- 2013-06-04 EA EA201992010A patent/EA201992010A1/en unknown
- 2013-06-04 EA EA201791592A patent/EA033956B1/en unknown
- 2013-06-04 PE PE2014002383A patent/PE20150631A1/en active IP Right Grant
- 2013-06-04 WO PCT/US2013/044116 patent/WO2013184681A1/en not_active Ceased
- 2013-06-04 ES ES13800681.2T patent/ES2670683T3/en active Active
- 2013-06-04 RS RS20210739A patent/RS61988B1/en unknown
- 2013-06-04 SI SI201331788T patent/SI3348553T1/en unknown
- 2013-06-04 US US14/406,520 patent/US9481663B2/en active Active
- 2013-06-04 CN CN202110417935.XA patent/CN113135892A/en active Pending
- 2013-06-04 MY MYPI2014703627A patent/MY187500A/en unknown
- 2013-06-04 LT LTEP19169275.5T patent/LT3533792T/en unknown
- 2013-06-04 HK HK15111086.5A patent/HK1210175A1/en unknown
- 2013-06-04 ME MEP-2020-163A patent/ME03815B/en unknown
- 2013-06-04 SG SG10201610248SA patent/SG10201610248SA/en unknown
- 2013-06-04 IL IL267608A patent/IL267608B2/en unknown
- 2013-06-04 PL PL19169275T patent/PL3533792T3/en unknown
- 2013-06-04 TR TR2018/08939T patent/TR201808939T4/en unknown
- 2013-06-04 SG SG10201610249TA patent/SG10201610249TA/en unknown
- 2013-06-04 EA EA201492272A patent/EA028791B1/en unknown
-
2014
- 2014-12-01 CR CR20140549A patent/CR20140549A/en unknown
- 2014-12-04 IL IL236055A patent/IL236055A0/en unknown
- 2014-12-04 NI NI201400142A patent/NI201400142A/en unknown
- 2014-12-04 PH PH12014502714A patent/PH12014502714A1/en unknown
- 2014-12-05 GT GT201400283A patent/GT201400283A/en unknown
- 2014-12-05 EC ECIEPI201430098A patent/ECSP14030098A/en unknown
- 2014-12-05 CL CL2014003331A patent/CL2014003331A1/en unknown
- 2014-12-09 CO CO14270612A patent/CO7240407A2/en unknown
-
2015
- 2015-01-06 ZA ZA2015/00076A patent/ZA201500076B/en unknown
-
2016
- 2016-07-26 PH PH12016501470A patent/PH12016501470B1/en unknown
- 2016-09-12 US US15/262,522 patent/US9994545B2/en active Active
- 2016-12-19 HK HK16114389.2A patent/HK1226066A1/en unknown
-
2017
- 2017-01-17 AU AU2017200298A patent/AU2017200298B2/en active Active
- 2017-02-15 JP JP2017025746A patent/JP6345821B2/en active Active
- 2017-12-22 AU AU2017279807A patent/AU2017279807B2/en active Active
-
2018
- 2018-05-09 US US15/975,449 patent/US10308630B2/en active Active
- 2018-05-23 JP JP2018098638A patent/JP2018141009A/en active Pending
- 2018-05-31 IL IL259738A patent/IL259738B/en active IP Right Grant
- 2018-07-06 CY CY20181100712T patent/CY1120393T1/en unknown
-
2019
- 2019-04-15 US US16/384,002 patent/US10526310B2/en active Active
- 2019-07-10 US US16/507,780 patent/US10556882B2/en active Active
- 2019-12-11 US US16/710,785 patent/US10766875B2/en active Active
-
2020
- 2020-06-15 IL IL275413A patent/IL275413A/en unknown
- 2020-07-29 US US16/942,069 patent/US10934271B2/en active Active
- 2020-08-31 HR HRP20201387TT patent/HRP20201387T1/en unknown
- 2020-09-23 CY CY20201100901T patent/CY1123427T1/en unknown
-
2021
- 2021-01-26 US US17/158,806 patent/US12018008B2/en active Active
- 2021-06-08 HR HRP20210909TT patent/HRP20210909T1/en unknown
- 2021-07-02 CY CY20211100595T patent/CY1124831T1/en unknown
- 2021-11-02 LU LU00236C patent/LUC00236I2/fr unknown
- 2021-11-02 NO NO2021046C patent/NO2021046I1/en unknown
- 2021-11-03 LT LTPA2021525C patent/LTC3533792I2/lt unknown
- 2021-11-03 NL NL301144C patent/NL301144I2/en unknown
- 2021-11-03 FR FR21C1050C patent/FR21C1050I2/en active Active
- 2021-11-04 CY CY2021032C patent/CY2021032I2/en unknown
- 2021-11-04 HU HUS2100047C patent/HUS2100047I1/en unknown
-
2024
- 2024-05-13 US US18/662,345 patent/US20250092011A1/en not_active Abandoned
-
2025
- 2025-04-18 US US19/183,276 patent/US20260109683A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501470A1 (en) | Crystalline forms of an androgen receptor modulator | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| MX2013006040A (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis. | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| IN2012DN02177A (en) | ||
| IN2012DN00754A (en) | ||
| UA107334C2 (en) | Alkaloid aminoester derivatives and their drug compositions | |
| UA102857C2 (en) | Quinuclidine carbonate derivatives and use thereof | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| MX2015007051A (en) | Diazole lactams. | |
| EA032271B9 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| MX353331B (en) | Solid forms of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihy dro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine hydrochloride. | |
| MX2015012043A (en) | Muscarinic agonists. | |
| WO2015079415A9 (en) | Amorphous cobicistat solid dispersion | |
| UA115310C2 (en) | SPIROTSYKLICHNI compounds based on derivatives of 2-OKSINDOLU, CONTAINING CORE SPIRO [indole-3,1'-pyrrolo [3,4-c] pyrrole] and the remains of biogenic sulfur-containing amino acids, the way they receive and pharmaceutical compositions on their basis | |
| TN2011000063A1 (en) | Quinuclidine carbonate derivatives and medicinal composition thereof |